Hepatitis Forums

Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on October 17, 2018, 10:29:14 am

Title: As Hep B Treatment, Viread Tied to Lower Liver Cancer Risk Than Baraclude
Post by: Hep Editors on October 17, 2018, 10:29:14 am
Treating chronic hepatitis B virus (HBV) with Viread (tenofovir disoproxil fumarate, or TDF) is associated with a lower risk of hepatocellular carcinoma (HCC, the most common form of liver cancer) compared with using Baraclude (entecavir), Medscape reports.

Publishing their findings in JAMA Oncology researchers analyzed data from a nationwide population cohort study of South Koreans with chronic hep B who started treatment for the virus for the first time with Baraclude (11,464 people) or Viread (12,692 people) between January 2012 and December 2014. The data came from the Korean National Health Insurance Service database.